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Key Points




RAB31 is a RUNX1
target; regulates
VWF, epidermal
growth factor
receptor, and
mannose-6-phosphate
trafﬁcking; and is
downregulated in
RHD.
EE and vesicle
trafﬁcking defects
induced by RAB31
downregulation likely
contribute to
a-granule defects with
RUNX1 mutation.

Transcription factor RUNX1 is a master regulator of hematopoiesis and
megakaryopoiesis. RUNX1 haplodeﬁciency (RHD) is associated with thrombocytopenia
and platelet granule deﬁciencies and dysfunction. Platelet proﬁling of our study patient
with RHD showed decreased expression of RAB31, a small GTPase whose cell biology
in megakaryocytes (MKs)/platelets is unknown. Platelet RAB31 messenger RNA was
decreased in the index patient and in 2 additional patients with RHD. Promoter-reporter
studies using phorbol 12-myristate 13-acetate–treated megakaryocytic human
erythroleukemia cells revealed that RUNX1 regulates RAB31 via binding to its
promoter. We investigated RUNX1 and RAB31 roles in endosomal dynamics using
immunoﬂuorescence staining for markers of early endosomes (EEs; early endosomal
autoantigen 1) and late endosomes (CD63)/multivesicular bodies. Downregulation
of RUNX1 or RAB31 (by small interfering RNA or CRISPR/Cas9) showed a striking
enlargement of EEs, partially reversed by RAB31 reconstitution. This EE defect was
observed in MKs differentiated from a patient-derived induced pluripotent stem cell line
(RHD-iMKs). Studies using immunoﬂuorescence staining showed that trafﬁcking of
3 proteins with distinct roles (von Willebrand factor [VWF], a protein trafﬁcked to
a-granules; epidermal growth factor receptor; and mannose-6-phosphate) was impaired
at the level of EE on downregulation of RAB31 or RUNX1. There was loss of plasma
membrane VWF in RUNX1- and RAB31-deﬁcient megakaryocytic human erythroleukemia
cells and RHD-iMKs. These studies provide evidence that RAB31 is downregulated in
RHD and regulates megakaryocytic vesicle trafﬁcking of 3 major proteins with diverse
biological roles. EE defect and impaired vesicle trafﬁcking is a potential mechanism for
the a-granule defects observed in RUNX1 deﬁciency.
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Introduction
Rab proteins are small GTPases that control intracellular vesicle trafﬁcking.1-3 They function as molecular switches that alternate between
guanosine triphosphate (GTP)-bound active form and guanosine
diphosphate–bound inactive form to coordinate vesicle trafﬁcking
through interaction with effector molecules that bind the GTP-bound
form. Intracellular trafﬁcking events regulated by Rab proteins include
budding, ﬁssion of transporting vesicles from donor membranes, their
movement along cytoskeletal tracks, and docking/fusion to acceptor
membranes. More than 70 members of the Rab family have been
identiﬁed, and they play speciﬁc roles in vesicle trafﬁcking, depending
on their cellular locations.1,2,4 At least 40 Rab proteins are recognized
in human platelets,4 but speciﬁc roles in vesicle trafﬁcking are
unknown in platelets or megakaryocytes for the majority.
RAB31 (Ras-related protein in brain 31), a member of the RAB5
subfamily of Rab GTPases, was cloned from human platelets,5 and
it shared 82% homology with RAB22B protein identiﬁed in human
melanocytes.6 RAB31 regulates anterograde and retrograde membrane trafﬁcking between the Golgi/trans-Golgi network (TGN) and
the endosomes and plasma membrane.3,7,8 It is localized in tubular
vesicular carriers that bud from TGN, travels along microtubules, and
fuses with endocytic membranes, indicating its critical involvement in
TGN to endosome transport.7,8 Previous studies have shown that
RAB31 regulates epidermal growth factor receptor (EGFR) trafﬁcking from early endosomes (EEs) to late endosomes in A431 neuronal cells9 and mannose-6-phosphate receptor (M6PR) trafﬁcking
from TGN to endosomes in HeLa cells.10 RAB31 has been implicated in the maintenance of Golgi structure with a disruption on
RAB31 depletion, insulin-driven glucose transporter-4 trafﬁcking in
adipocytes,11 and phagocytosis in macrophages.12 RAB31 has also
been implicated in human cancers, with increased expression in
some such as colorectal cancers.13,14 However, little is known about
the role and function of RAB31 or the mechanisms regulating its
expression in megakaryocytes and platelets.
The RUNT-related transcription factor 1, RUNX1 (also called AML1
or CBFA2), is a master regulator of hematopoiesis and a major
player in megakaryocyte/platelet biology.15-19 Human monoallelic
RUNX1 mutations are associated with familial thrombocytopenia,
platelet a-granule and dense granule deﬁciencies, impaired platelet
responses to activation, abnormalities in megakaryocyte differentiation, and a predisposition to myeloid malignancies.15,17,20 Our platelet expression proﬁling studies using Affymetrix microarrays in a
patient with a heterozygous RUNX1 mutation showed that several
genes were downregulated,21 and our subsequent studies found
that some of them are transcriptional targets of RUNX1.18,22,23
These proﬁling studies also showed21 that platelet RAB31 expression was decreased in our study patient with RUNX1 haplodeﬁciency (RHD). In the current studies, we show that RAB31 is a
direct RUNX1 transcriptional target and is downregulated in RHD.
To understand the role of RAB31 in megakaryocyte/platelet biology,
we studied the trafﬁcking of 3 proteins with distinct biological roles:
von Willebrand factor (VWF), an a-granule protein synthesized by
human megakaryocytes; EGFR; and M6PR. We provide the ﬁrst evidence that RAB31 regulates endosomal trafﬁcking of these proteins
in megakaryocytic human erythroleukemia (HEL) cells and that this
trafﬁcking is impaired and associated with an EE defect on RUNX1
downregulation. This EE defect was observed in megakaryocytes
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differentiated from a RHD patient–derived induced pluripotent stem
cell (iPSC) line. These studies advance impaired RAB31-related
vesicle trafﬁcking as a potential mechanism for the a-granule
defects in patients with RHD.

Methods
Patient information
Patient P1 (a 40-year-old man) has life-long thrombocytopenia and
abnormal platelet function associated with a single point mutation
(c.352-1G.T) in intron 3 at the splice acceptor site for exon 4 leading to a frame shift with premature termination in the conserved RUNT
homology domain of RUNX1.24 Details of the platelet function abnormalities18,21,25-27 and expression proﬁling studies in this patient have
been described previously. We studied 2 other patients (an 8-year-old
boy [P2] and his 3-year-old sister [P3]) from an unrelated family with
thrombocytopenia and an RUNX1 mutation (c.508 1 1G.A). The
maternal grandmother and great uncle had a history of acute myeloid
leukemia. The patients had abnormal agonist-induced aggregation and
secretion on laboratory testing. The studies on the patients and control subjects were approved by Institutional Review Boards and were
performed after obtaining informed consent.

Cell culture
HEL cells from ATCC (Rockville, MD) were grown and induced in
RPMI 1640 medium as described previously.27 These cells were
treated with phorbol 12-myristate 13-acetate (PMA) (10 nM) to
induce megakaryocytic transformation unless speciﬁed otherwise.
iPSC-derived megakaryocytes (iMKs) were differentiated as described from an established control iPSC line, designated as
CHOPWT6 (Control 2 iPSC line in the study by Sullivan et al28)
and a patient-derived iPSC line29 derived from an RHD patient with
a monoallelic splice acceptor defect near exon 4 of RUNX1.17

Real-time polymerase chain reaction
Total RNA was extracted from platelets derived from whole blood of
healthy donors and the patients.23 The RNAs were subjected to ﬁrst
strand complementary DNA synthesis using Superscript III (Invitrogen/Thermo Fisher Scientiﬁc, Norristown, PA) and ampliﬁed by realtime polymerase chain reaction (PCR) using SYBR Green PCR
(Applied Biosystems, Foster City, CA) mix and primers (0.1 mM
each) for RAB31: forward 59 -GGAGCTCAAAGTGTGCCTTC-39
and reverse 59 -CGGCTGATTCCTTGAAAGAG-39 or for GAPDH:
forward 59 -AACTGTGTGGTC TTGAA CCTCCGT-39 and reverse
59 -ACACACTCTCATGCAGCTACCAT-39 . The real-time PCR parameters were as follows: 95 C for 10 minutes followed by 40 cycles
of 95 C for 15 seconds, 55 C for 20 seconds, and 72 C for 20
seconds using a Master Cycler Real-Time PCR system (Eppendorf,
Hauppauge, NY); relative abundances were calculated by the DDCT
method using GAPDH as the reference gene.

Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed on
HEL cells (1 3 106) treated with PMA (10 nM) for 24 hours using
the ChIP-It kit (Active Motif, Carlsbad, CA) and antibodies as
described previously.30 Chromatin samples were immunoprecipitated with anti-RUNX1 antibody (sc-8563x) or with normal immunoglobulin G (IgG) (sc-2028) from Santa Cruz Biotechnology (Dallas,
TX). Immunoprecipitated samples were analyzed by PCR using the
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primers (supplemental Table 1). Ampliﬁcation was performed by
using Go Taq Green Master Mix (Promega, Madison, WI) with one
cycle at 95 C for 2 minutes followed by 32 cycles of 95 C for 30
seconds, 62 C for 45 seconds, and 72 C for 60 seconds. Ampliﬁed products were analyzed by agarose gel electrophoresis.

Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were performed by
using HEL cell nuclear extracts as described31 with infrared-labeled
RAB31 probes (supplemental Table 2). RAB31 promoter region
22013/21 (from ATG) has 4 RUNX1 consensus sites. Doublestranded oligonucleotides encompassing these sites (RAB31 site I
probe 2816/2797, site II probe 2976/2957, site III probe
21506/21487, and site IV probe 22016/21997) were labeled
with infrared dye 700 (LI-COR Biosciences, Lincoln, NE). Binding
reaction between nuclear extract (6 mg) and probe was performed
on ice for 30 minutes. Supershift assays were performed with antiRUNX1 antibody (sc-8563) or normal IgG (sc-2028) (Santa Cruz
Biotechnology). The reaction mixture was resolved by electrophoresis using 5% TBE ready-made gels (Bio-Rad, Hercules, CA) and
visualized on an Odyssey Infrared Imaging System (LI-COR
Biosciences).

Promoter-reporter assays
The RAB31 wild-type (WT) promoter (-2023 bp/141 bp) and constructs with speciﬁc mutations in RUNX1 sites were generated by
using a directional PCR method with gene-speciﬁc primers incorporated with restriction sites (MluI or Nhe I at 59 side and Hind III or
Nhe I at 39 side). The PCR products were cloned into TOPO TA
cloning vector (Invitrogen/Thermo Fisher Scientiﬁc). The recombinant TOPO TA plasmid was digested with appropriate restriction
enzymes, and the promoter region was subcloned in between same
restriction sites of the pGL3-Basic promoter. Sequences were conﬁrmed by DNA sequencing on the ABI Prism 377 (Genewiz, South
Plainﬁeld, NJ). Promoter-reporter constructs were transfected individually along with a standard Renilla luciferase (in a 50:1 ratio) into
HEL cells (2 3 106) using Lipofectamine 2000 (Thermo Fisher Scientiﬁc, Philadelphia, PA). In parallel, promoter-less pGL3-Basic vector was also transfected in these experiments, and dual luciferase
assays were performed as described previously.31 The primer
sequences of WT construct and its mutants are shown in supplemental Table 3. Promoter activity was expressed as the ratio of ﬁreﬂy luciferase activity to Renilla luciferase activity relative to that of
the promoter-less vector. All transfection experiments were performed 3 times in triplicate.

RAB31 regulation by RUNX1
HEL cells (2 3 106) were cotransfected with WT RAB31 luciferase
promoter construct along with control small interfering RNA (siRNA)
or RUNX1 siRNA (100 nM each; Santa Cruz Biotechnology) to
determine downregulation of promoter activity. Cells were cotransfected with RAB31 WT luciferase construct and RUNX1 expression
vector, RUNX1-pCMV6-XL4, or its empty vector, pCMV-XL4 (1 mg
each; OriGene Technologies, Rockville, MD) to study the effect of
RUNX1 overexpression. pRL Renilla Luciferase Control Reporter
Vector (pRL-TK, 0.1 mg) was used in each transfection as an internal standard. Dual-luciferase assays were performed. Protein levels
were assessed in cell lysates by immunoblotting.30
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Immunoblotting
HEL cells were lysed in M-Per protein extraction reagent (Pierce
Biotechnology, Waltham, MA) with protease inhibitor cocktail (Active
Motif) and subjected to gel electrophoresis on 4% to 20% MiniPROTEAN TGX gels (Bio-Rad) and the protein transferred to polyvinylidene diﬂuoride membrane (Millipore, Billerica, MA). Blots were
probed with antibodies against RAB31 (ARP61983_P050; Aviva
Systems Biology, San Diego, CA), RUNX1 (sc-8563 or sc365644), or actin (sc-1616R) or M6PR (sc-365196) from Santa
Cruz Biotechnology, and mPR alpha polyclonal antibody (PA561376, Invitrogen/Thermo Fisher Scientiﬁc), and then with IRDyelabeled secondary antibodies (LI-COR Biosciences) using Odyssey
Infrared Imaging System (LI-COR Biosciences).

Nucleofection
HEL cells (1 3 106) were mixed with control siRNA or RUNX1
siRNA (100 nM each) or RAB31 siRNA (125 nM; Santa Cruz Biotechnology) or RUNX1 siRNA (100 nM) plus Rab31 expression
plasmid (4 mg; OriGene Technologies) individually and nucleofected
by using Amaxa cell line Nucleofector kit V in a Nucleofector 2b
device (Lonza, Morristown, NJ). The nucleofected cells were resuspended in the medium supplemented with PMA and incubated at
37 C with 5% carbon dioxide. After 24 hours, medium was aspirated, and cells were gently washed with 1X phosphate-buffered
saline, ﬁxed with 4% formaldehyde at room temperature for 15
minutes, and stored at 4 C. In parallel, cells were lysed for
immunoblotting.
Immunoﬂuorescence studies. Platelets and HEL cells were
seeded on human plasma ﬁbronectin-coated or poly-L-lysine–coated
coverslips. Cells were ﬁxed in phosphate-buffered saline containing
3.7% formaldehyde and permeabilized with 0.1% Triton X-100 before
immunostaining with antibodies as described previously.26 Where
indicated, cells were exposed to EGF (0.25 mg/mL) for 8 minutes
before seeding on coverslips. Cells were stained for markers of EEs
(early endosomal autoantigen 1 [EEA1]), late endosome/multivesicular bodies (MVBs) (CD63), and EGFR. The antibodies used are presented in supplemental Table 4. Images were obtained on an EVOS
microscope (Thermo Fisher Scientiﬁc) or a TCS SP5 confocal microscope (Leica Microsystems, Buffalo Grove, IL), using a 63X/1.40
numerical aperture oil immersion objective at room temperature and
EVOS or Leica imaging software, respectively. Post-acquisition processing and analysis were performed with Adobe Photoshop and
ImageJ32 and were limited to image cropping and brightness/contrast
adjustments applied to all pixels per image simultaneously. Particle
areas were determined from single-color thresholded images from at
least 3 submicron slices per cell with at least 50 cells per type, using
ImageJ with at least 50 cells per type; they are shown as mean 6
standard error of the mean. The ﬂuorophores used were ﬂuorescein
isothiocyanate, Cy3, and Cy5.
Generation of RAB31 knockout HEL cell lines. Singleguide RNA (sgRNA) pairs targeting RAB31 were designed for targeting and predicted off-target sites using online CRISPR Design
(http://crispr.mit.edu/) and CRISPOR (http://www.crispor.org). The
annealed sgRNAs were inserted into the AIO-GFP (Cas9) plasmid
containing dual U6 promoter-driven sgRNAs and enhanced
green ﬂuorescent protein–coupled Cas9 nuclease as described
elsewhere.33 The following oligonucleotides were used: sgRNA 1
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Statistical analysis for in vitro studies
Results of the in vitro studies are expressed as the mean 6 standard
error of the mean. Differences were compared by using the t test.
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Results
Decreased platelet RAB31 expression in RHD
On platelet expression proﬁling using Affymetrix U133 Gene Chips,
RAB31 expression was decreased in our patient (P1) with a RUNX1
mutation compared with healthy control subjects (fold change,
0.28775; P 5 .008).21 We validated this by real-time PCR using a
fresh sample (Figure 1A). Platelet RAB31 messenger RNA by realtime PCR was decreased in 2 additional patients, P2 and P3 (siblings
from an unrelated family with RHD) (Figure 1B). By immunoblotting,
platelet RAB31 was decreased in patients P2 and P3 compared with
healthy subjects (Figure 1C).

RAB31 regulation by RUNX1
RAB31 promoter sequence (2023 bp from ATG codon) revealed 4
consensus RUNX1 binding sites at 59 -813/-808-39 (from ATG; Site
I), 59 -972/-967-39 (Site II), 59 -1500/-1495-39 (Site III) and 59 -2007/2002-39 (Figure 2A). The ChIP assay was performed on HEL cell
chromatin using an anti-RUNX1 antibody. PCR ampliﬁcation of chromatin immunoprecipitated with the anti-RUNX1 antibody showed
enrichment of promoter regions with site II and site IV; no enrichment was noted with normal IgG (Figure 2B). The chromatin regions
containing sites I and III were not enriched. These results indicate
that RUNX1 binds to RAB31 promoter.
EMSA was performed by using HEL nuclear extracts and labeled
RAB31 oligos encompassing each RUNX1 consensus site (supplemental Table 2). These studies revealed RUNX1 binding to probes
containing sites II and IV (Figure 2C) but not to probes containing
sites I and III (not shown). In studies with the labeled probe containing site II, there was protein binding (lane 2), which was competed
with excess unlabeled probe (lane 3). The binding was not altered
by normal IgG (lane 4) but was inhibited by RUNX1 antibody (lane
5). Similar results were observed in studies with the oligo containing
site IV. These ﬁndings are consistent with ChIP analysis (Figure 2B).
Together, the ChIP and EMSA indicate that RUNX1 binds to consensus sites I and IV. In promoter-reporter studies (Figure 2D), there
was a striking loss of promoter activity with mutation of site IV of the
13 SEPTEMBER 2022 • VOLUME 6, NUMBER 17

Figure 1. RAB31 expression in platelets from RUNX1-haplodeﬁcient
patients (P) and normal control subjects (N). Platelet RAB31 messenger RNA
(mRNA) levels by quantitative PCR in the index patient (P1) (A) or in 2 siblings
(P2 and P3) from an unrelated family (B) with a RUNX1 mutation compared with 5
normal subjects (N1-N5). mRNA levels normalized to glyceraldehyde-3-phosphate
dehydrogenase expression. (C) Platelet RAB31 by immunoblotting in 3 patients
(P1-P3) and 5 healthy subjects (N1-N5). Protein expressions are shown in the ratio
of RAB31 to actin.

RAB31 promoter compared with the WT construct, indicating that
this site was functional. Mutation of site II caused enhancement in
promoter activity, suggesting that it is a negative regulator. There
was no change in promoter activity with mutations of sites I and III.
RUNX1 overexpression in HEL cells increased endogenous RUNX1
and RAB31 protein expression (Figure 3A) and RAB31 promoter
activity of the WT luciferase construct (Figure 3B). RUNX1 siRNA
inhibited endogenous RUNX1 and RAB31 protein expression
(Figure 3C) and promoter activity (Figure 3D). Together, these ﬁndings indicate that RAB31 is regulated by RUNX1.

EE defect and altered EGFR endosomal trafﬁcking
in RUNX1 or RAB31 deﬁciency
RAB31 has been reported to regulate EGFR endosomal trafﬁcking
in mouse neural progenitor cells.9 We studied the effects of
RUNX1 and RAB31 siRNAs in megakaryocytic HEL cells using
immunoﬂuorescent staining for markers of EEs (EEA1)34 (Figure 4)
and late endosomes/MVBs (CD63)35 and EGFR (Figure 5).
With siRNA RUNX1 depletion, there was a striking enlargement of
EEA1 particles (Figure 4A-B). Similar ﬁndings were noted on siRNA
knockdown of RAB31 with increased size of EEA1 particles. This
was partially reversed by ectopic expression of RAB31 in RUNX1depleted cells, suggesting a RAB31 role in the observed alterations.
Immunoblotting conﬁrmed the expected knockdown of RUNX1 or
RAB31 and RAB31 reconstitution in RUNX1-depleted cells
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Figure 2. Characterization of RAB31 promoter. (A) RAB31 promoter region (22023 bp from ATG codon) showing 4 RUNX1 consensus-binding sites. (B) RUNX1
binding to RAB31 upstream region by ChIP. PCR ampliﬁcation of HEL cell chromatin immunoprecipitated by IgG (lane 1) and RUNX1 antibody (lane 2); PCR ampliﬁcation
of input or total DNA (lane 3) and ampliﬁcation of genomic DNA (gDNA) (lane 4) using RAB31 primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
ampliﬁed as an internal control. (C) EMSA using WT nucleotide probes carrying RUNX1-binding site II (2957/2976; left) and site IV (21997/22016; right) in RAB31
promoter and PMA-treated HEL nuclear extracts. EMSA using site II probe (left panel) lane 1, no extract; lane 2, protein binding to the probe; lane 3, loss of protein binding
by competition with excess unlabeled probe; lane 4, no loss of binding by competition with normal IgG; and lane 5, loss of protein binding on competition with anti-RUNX1
antibody. EMSA using site IV probe (right panel, lanes 1-5): similar results were obtained with the probe with site II. Representative of 3 independent experiments.
(D) Luciferase reporter studies on RAB31 promoter in PMA-treated HEL cells. Left panel: WT RAB31 promoter with 4 RUNX1 sites (red boxes) and constructs with
speciﬁc mutants (blue boxes). Right panel: shown is luciferase activity. Site II mutation shows increase in activity compared with WT construct; site IV mutation decreased
activity, indicating sites II and IV are functional. Presented as mean 6 standard error of the mean of 3 independent experiments in triplicate. NS, not signiﬁcant.
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Figure 3. Effect of RUNX1 overexpression and RUNX1 depletion by siRNA on RAB31 protein expression and promoter activity. (A) Effect of RUNX1
overexpression. Immunoblotting of RUNX1 and RAB31 of HEL lysates transfected with RUNX1 expression plasmid (RUNX1-pCMV6) and empty plasmid (PCMV6). Actin
was the loading control. Presented as mean 6 standard error of the mean (SEM) of 3 independent experiments. (B) Effect of RUNX1 overexpression on promoter activity
(luciferase). RAB31 WT promoter construct was cotransfected with RUNX1 expression plasmid or empty plasmid in HEL cells. Promoter activity was enhanced with RUNX1
plasmid. Activity shown as mean 6 SEM of 3 independent experiments in triplicate. (C) Effect of RUNX1 downregulation (siRNA). Immunoblotting of HEL lysates transfected
with control or RUNX1 siRNA. Actin was the loading control. Presented as mean 6 SEM of 3 independent experiments. (D) Effect of RUNX1 siRNA on promoter activity.
RAB31 WT promoter construct was cotransfected with control or RUNX1 siRNA. Promoter activity was reduced with RUNX1 siRNA. Presented as mean 6 SEM of
3 independent experiments in triplicate. RUNX1 siRNA inhibited RAB31 protein expression and promoter activity. NS, not signiﬁcant.

(Figure 4C). RHD-iMKs also showed an increase in EEA1 particle
size (Figure 4D), providing evidence of the EE defect.
Exposure of HEL cells to EGF for 8 minutes at 37 C resulted in
internalization of membrane EGFR (Figure 5A). In control cells,
colocalization of EGFR with EEA1 appeared to be in the perinuclear
area where RAB31 has been shown to localize.3,10 On RUNX1
knockdown, there was a prominent increase in EEA1-positive
13 SEPTEMBER 2022 • VOLUME 6, NUMBER 17

granule size with enrichment by EGFR (Figure 5A,C), suggesting a
block in the endocytic pathway at the EEA1 level. To investigate
RAB31 role in receptor/vesicle trafﬁcking in HEL cells, we generated RAB31-deleted (knockout) HEL cell lines using CRISPR/
Cas9. In RAB31 knockout cells, EEA1 vesicles were enlarged compared with control cells (Figure 5B). In WT cells, EGFR showed
partial colocalization with CD63, a marker of late endosome/
MVB, and with EEA1. In RAB31 knockout cells, EGFR partially
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colocalized with EEA1 and strikingly in the enlarged EEA1-positive
vesicles (Figure 5B-C). Together, these studies suggested that
RUNX1 deﬁciency and RAB31 knockout induce a marked alteration
in EE morphology, attributed to impaired EE maturation,36 and disruption of EGFR trafﬁcking with accumulation in EEs.

Altered VWF trafﬁcking on in RUNX1- and
RAB31-deﬁcient cells
VWF is synthesized by MK and is present in platelet a-granules. In
our previous studies,22 VWF trafﬁcking was distorted on knockdown
of RUNX1 or of the small GTPase RAB1B, a RUNX1 target, with
altered RAB1B-mediated VWF trafﬁcking from endoplasmic reticulum to the Golgi. In control HEL cells, there was heterogeneous patterning, and VWF exhibited a combination of a ringed band pattern
concentrated near the plasma membrane and was being condensed
in the perinuclear area (Figures 6A-B). With siRNA RUNX1 knockdown, the peripheral banding pattern of VWF was absent (Figure
6A) with dispersion in the perinuclear area, indicating altered VWF
trafﬁcking. Ectopic expression of RAB31 did not reverse these alterations. In RAB31 knockout cells, there was little to no VWF detectable at the plasma membrane or in CD63– vesicles, whereas
perinuclear colocalization with CD63 was prominent (Figure 6B),
consistent with accumulation in late endosomes/MVBs. These
13 SEPTEMBER 2022 • VOLUME 6, NUMBER 17

ﬁndings suggest a defect in VWF handling on RAB31 knockout,
with loss of plasma membrane VWF and retention in late endosomes/MVBs. Studies in control iMKs (Figure 6C) revealed the
plasma membrane banding of VWF, which was lost in RHD-iMKs.

Studies on M6PR in RUNX1- and
RAB31-deﬁcient cells
M6PR are transmembrane glycoproteins that regulate trafﬁcking of
lysosomal enzymes to lysosomes, where they are degraded.37,38
M6PR binds newly synthesized lysosomal hydrolases in TGN and
delivers them to pre-lysosomal compartments. In HeLa cells, RAB31
has been reported to regulate trafﬁcking of calcium-dependent
M6PR from TGN to endosomes.10 In the present studies, upon
RUNX1 knockdown or RAB31 knockout, there was a markedly
increased size of EEA1 particles compared with control cells with
colocalization of M6PR with EEA1 (Figure 7A-B). On immunoblotting, M6PR was increased on siRNA RUNX1 knockdown and in 5
of 6 clones of RAB31 knockout cells (Figure 7C), suggesting accumulation of M6PR.

Discussion
These studies provide the ﬁrst evidence that small GTPase RAB31
is regulated in megakaryocytic cells by RUNX1 (Figures 2 and 3)
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and that platelet expression of RAB31 is decreased in patients with
RHD (Figure 1). The cell biological roles of RAB31 in MK/platelets
are unknown. Our studies show that RAB31 regulates the trafﬁcking
of 3 proteins with diverse functions (EGFR, VWF, and M6PR), and
their trafﬁcking is defective, with striking alterations in EEs on downregulation of RAB31, as well as of RUNX1, which regulates its
expression.
A consistent abnormality noted in our studies on knockdown of
RUNX1 or RAB31 in HEL cells was a striking increase in size of
EEs (Figures 4-6). This was also noted in RHD-iMKs (Figure 4D).
These morphologic changes have been considered as a marker of
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defective EE maturation.36 This abnormality in RUNX1-deﬁcient cells
was reversed, partially rescued by RAB31 (Figure 4A), suggesting a
role for RAB31 in the endosomal defect. EEs are one of the earliest
endocytic vesicles to receive proteins, and they play a major function
in their sorting into subsequent recycling, secretory, and degradative
compartments.1,39 Enlarged EEs have been observed in Alzheimer
disease and Niemann-Pick disease and are attributed to defective
endosomal trafﬁcking.36 Defective fusion of EEs and subsequent ﬁssion are postulated to result in the increase in size and number.36,40
We show that RUNX1 deﬁciency induces a similar defect in MK
cells, mediated, at least in part, by RAB31 downregulation.
Our studies provide evidence for a role of RAB31 in the trafﬁcking
in megakaryocytic cells of VWF, EGFR, and M6PR, which have distinct roles in cell biology. Their trafﬁcking was altered on RAB31
knockdown along with altered EEs. Studies in non-MK cells have
shown that RAB31 regulates protein trafﬁcking from Golgi to early
endosomes and to other compartments.8-10 We found EGFR colocalization in the enlarged EEs on downregulation of RUNX1 or
RAB31 (Figure 4), consistent with a partial block in trafﬁcking at
EEs. Rab31 is a member of the RAB5 family, implicated in early
endocytosis.1,39 Because our studies were performed in cells
exposed to EGF, which stimulates endocytosis of EGFR, they suggest an effect on the handling of proteins from the surface membrane. This is relevant because platelets/MKs incorporate numerous
proteins by endocytosis,41 the mechanism by which ﬁbrinogen and
factor V are incorporated into a-granules42; neither is synthesized
by human MKs.
We provide evidence that RAB31 regulates trafﬁcking of VWF; this
is important because VWF is synthesized by MKs and sequestered
in a-granules, and defects involving a-granules and their constituents are a hallmark of RHD.18 We have shown that platelet VWF is
decreased in patients with RHD and in megakaryocytic cells by
RUNX1 downregulation.22 VWF trafﬁcking in megakaryocytic cells
is altered by downregulation of RUNX1 and by small GTPase
RAB1B (also, a RUNX1 target). We now show a RAB31 role in
VWF trafﬁcking, distinct from that of RAB1B. In WT cells, VWF is
concentrated near the plasma membrane and in the perinuclear
area (Figure 6). With siRNA RUNX1 knockdown, there was a loss
of the peripheral membrane banding pattern (Figure 6A). This was
also noted in RHD-iMK (Figure 6C). In RAB31 knockout cells,
plasma membrane VWF was lost, with prominent perinuclear colocalization with CD63 (Figure 6B), the latter suggesting accumulation
in the MVBs/late endosomes. These ﬁndings suggest VWF handling is defective on RAB31 knockout. In RUNX1-deﬁcient HEL
cells, ectopic RAB31 expression did not rescue the plasma membrane VWF (Figure 6A). We have shown22 that RAB1B regulates
VWF trafﬁcking from the endoplasmic reticulum to the Golgi,
upstream of the steps recognized to be regulated by RAB31 (from
TGN to EE and to late endosome).10 Thus, the effects of RUNX1
knockdown reﬂect combined alterations in RAB1B and RAB31,
and possibly other RUNX1-regulated genes.21 We postulate that
the inability of RAB31 to rescue membrane VWF in RUNX1-deﬁcient cells (Figure 6A) may be related to the concurrent aberration
in the upstream step (from Golgi to EE) due to RAB1B downregulation.22 Overall, these studies add RAB31 to the list of regulators of
VWF trafﬁcking.43
M6PRs regulate trafﬁcking of lysosomal enzymes from the TGN to
lysosomes.37,38 On downregulation of RUNX1 or RAB31, there
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was striking M6PR colocalization in the enlarged EEs, with an
increase in cell lysates (Figure 7), suggesting altered trafﬁcking and
accumulation. Little is known regarding the role of M6PR in MK/platelets. M6pr2/2 mice platelets had structural alterations, increased
adhesion to collagen, and decreased heparanase (the predominant
platelet lysosomal enzyme) associated with increased plasma levels,
consistent with its mistargeting; the mice had a prothrombotic phenotype.44 Interestingly, our previous studies found impaired secretion of lysosomal enzymes by RHD platelets,27 suggesting a
potential link to aberrant M6PR trafﬁcking.
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a-granule deﬁciencies are well established in RHD with decreases in
several proteins (PF4, b-thromboglobulin, VWF)18,22; the mechanisms
are not fully understood. They likely reﬂect alterations in multiple
RUNX1-regulated genes. Our studies advance the concept that
altered protein trafﬁcking due to downregulation of RUNX1-regulated
RAB proteins constitutes a hitherto unrecognized mechanism, along
with other mechanisms. For example, PF4 is a transcriptional target
of RUNX1,45 and decreased synthesis contributes to the low levels.
Platelet albumin and ﬁbrinogen are decreased in RHD, and their
platelet endocytosis is impaired.46 Overall, our studies provide new
insights into the role of RAB31 in protein trafﬁcking in MK cells,
especially of VWF, and advance understanding of the mechanisms
underlying the granule defects in RHD.
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